Technology

Verona Pharma

$7.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-3.32%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, and ETFs commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom. The listed name for VRNA is Verona Pharma plc American Depositary Share.

CEO
David S. Zaccardelli
Employees
25
Headquarters
London, Greater London
Founded
2005
Market Cap
389.75M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
36.22K
High Today
$7.80
Low Today
$7.46
Open Price
$7.65
Volume
45.15K
52 Week High
$15.71
52 Week Low
$2.01

Collections

VRNA Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

SHYF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure